DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression
Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.
How this was made

The 30-second read
Why it matters
Earnings beat on top line but margin compression may temper short‑term price moves; guidance lift is modest.
Market read
The release provides fresh data for traders focused on health‑tech and AI‑enabled healthcare platforms.
What to watch
The partnership with UpToDate and entry into paid search could unlock new revenue streams beyond the current guidance horizon.
Background
Doximity reported Q3 2026 results, highlighting AI product adoption, new hospital clients, and a partnership with UpToDate.
Ticker impact
Q3 2026 earnings release with revenue beat, margin compression and updated full-year guidance.
likely pressure as investors weigh margin compression against revenue beat and modest guidance raise
The mix of a revenue beat and margin decline creates uncertainty, prompting short‑term downside risk despite a slight guidance uplift.
Market effects
AI‑driven health‑tech firms may see heightened scrutiny on margin sustainability despite usage growth.
U.S. healthcare‑tech sector could experience modest volatility as peers react to Doximity's margin trends.
Limited to U.S. listed health‑tech equities; no broader macro impact.
Counterpoint
Investors could view the revenue beat and expanding AI client base as a catalyst for upside, betting margin compression is temporary.
Key entities
- companyDoximity
U.S. digital health platform (ticker DOCS).
- companyUpToDate
Clinical reference partner integrated with Doximity.


